Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years (Q47871792)

6 February 2018

title

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years (English)

1 reference

6 February 2018

0 references

0 references

1 reference

J P H Wilding

1

1 reference

6 February 2018

V Woo

2

1 reference

6 February 2018

K Rohwedder

3

1 reference

6 February 2018

J Sugg

4

1 reference

6 February 2018

S Parikh

5

1 reference

6 February 2018

Dapagliflozin 006 Study Group

6

1 reference

6 February 2018

publication date

29 August 2013

1 reference

6 February 2018

Diabetes, Obesity and Metabolism

published in

1 reference

6 February 2018

volume

16

1 reference

6 February 2018

issue

2

1 reference

6 February 2018

page(s)

124-136

1 reference

6 February 2018

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

cites work

1 reference

Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.

21 January 2018

1 reference

Is glycemic control improving in U.S. adults?

21 January 2018

1 reference

The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Insulin-associated weight gain in diabetes--causes, effects and coping strategies

21 January 2018

1 reference

Active sugar transport in health and disease

21 January 2018

1 reference

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

21 January 2018

1 reference

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

21 January 2018

1 reference

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

21 January 2018

1 reference

Combining insulin and oral agents

21 January 2018

1 reference

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

21 January 2018

1 reference

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

21 January 2018

1 reference

Improving efficiency of inferences in randomized clinical trials using auxiliary covariates

21 January 2018

1 reference

Intensive glycemic control and cardiovascular disease: an update

21 January 2018

1 reference

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Card

21 January 2018

1 reference

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

Long-term effects of intensive glucose lowering on cardiovascular outcomes

21 January 2018

1 reference

Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study

21 January 2018

1 reference

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

21 January 2018

1 reference

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

21 January 2018

1 reference

Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.

21 January 2018

1 reference

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

21 January 2018

1 reference

In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12187

1 reference

6 February 2018

1 reference

6 February 2018